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Evidence has supported obesity as a risk factor for both benign prostate hyperplasia (BPH) and prostate
cancer (PCa). Obesity causes several mechanisms including increased intra-abdominal pressure, altered
endocrine status, increased sympathetic nervous activity, increased inﬂammation process, and oxidative
stress, all of which are favorable in the development of BPH. In PCa, there are several different mecha-
nisms, such as decreased serum testosterone, peripheral aromatization of androgens, insulin resistance,
and altered adipokine secretion caused by inﬂammation, which may precipitate the development of and
even cause high-grade PCa. The role of obesity in prostatitis still remains unclear. A greater under-
standing of the pathogenesis of prostate disease and adiposity could allow the development of new
therapeutic markers, prognostic indicators, and drug targets. This review was made to help better un-
derstanding of the association between central obesity and prostate diseases, such as prostatitis, BPH,
and PCa.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity has risen alarmingly within the past few years, with an
incidence of approximately one case in every three adults in the
USA, compared with one in six adults 2 decades ago.1 Global
prevalence of obesity in men in Europe and Asia ranges from 4% to
30%.2e6 According to the Riset Kesehatan Dasar7 (Indonesia) in 2007,
the prevalence of obesity in populations above 15 years of age was
10.3%. This number has grown approximately 20% within less than
5 years.8 This geographic pattern can be explained, at least in part,
by different socioeconomic conditions, as well as by lifestyle
(sedentary lifestyle and lack of physical activity) and nutritional
factors (western diet).
It is well known that obesity is associated with an increased risk
of heart disease and diabetes. Most of these excess deaths were
attributed to coronary artery disease, diabetes, and kidney disease.
There are no clear indications that the obesity prevalence is
returning back to healthier levels.9 Recent studies have also looked
into its relationship with prostate disease. 10e12 The aim of this
study is to evaluate the association between central obesity andto Mangunkusumo Hospital,
l Jakarta, DKI Jakarta, 10430,
. Umbas).
ciﬁc Prostate Society, Published bprostate disease [prostatitis, benign prostate hyperplasia (BPH),
and prostate cancer (PCa)].
2. Deﬁnition of obesity
The World Health Organization and The National Institutes of
Health deﬁne overweight as a body mass index (BMI) of greater
than 25 kg/m2, and obesity as BMI of greater than 30 kg/m2,
whilst in Indonesia, according to the Riset Kesehatan Dasar7 by
the Health Ministry in 2010, overweight is deﬁned as a BMI of
between 25 kg/m2 and 27 kg/m2and obesity is more than 27.1 kg/
m2.8 Though easy to determine, BMI has its limitations, such as
the inability to both differentiate between fat and muscle, and
measure fat distribution in the body (since fat in different regions
may contribute different functions), especially in elderly
individuals.13e15
Central obesity is known to be more dangerous than general
obesity because it is able to produce hormonal and systemic
modiﬁcations leading to inﬂammation. Waist circumference (WC)
in determining visceral adiposity has been used in various studies
as an alternative measurement and deﬁnition of central obesity.16
WC can be measured either at the narrowest torso circumference
or at the midpoint between the lower ribs and iliac crest.17 This
relatively practical application has led to the wide use of WC in
many studies as a tool to measure central obesity.18e20 The mea-
surement of WC, which represents abdominal adipose tissue, has
been reported to increase at a faster rate than BMI, which countsy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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mass. In addition, the adverse health consequences of obesity may
be underestimated by trends of BMI.21,22 Central obesity can be
diagnosed if WC is larger than 90 cm in men and 80 cm in
women.23
There is evidence linking the amount of adipose tissue to the
level of both acute and chronic inﬂammation.24e30 However,
there are certain types of adipose tissue, which vary from
different adipose tissue location and composition, that are
strongly correlated with inﬂammation.6,19,21,22,24,31,32 Adipose
tissue is divided into two categories: visceral (abdominal/central)
adipose tissue (VAT) and subcutaneous (peripheral) adipose tis-
sue (SAT).25 VAT has a distinct characteristic in terms of function
and inﬂammation compared to SAT. VAT is mainly composed of
omental, mesenteric fat, and retroperitoneal fat masses by
delineation along the dorsal borderline of the intestines and the
ventral surface of the kidney.30 Adipocytes from VAT appear to
have reduced capacity for lipogenesis and greater capacity for
lipolysis than SAT cells, with VAT containing more proin-
ﬂammatory and angiogenic cytokines than SAT.21 Fox et al24
demonstrated that the VAT compartment is metabolically active,
secreting such vasoactive substances as inﬂammatory markers
and adipocytokines, which may contribute to its role in the
inﬂammation process. Alterations in plasma lipoprotein levels,
particularly increased triglyceride and decreased high density li-
poprotein levels, has also been associated with VAT distribution.30
Because obesity often associates with a sedentary lifestyle, and
physical activity decreases the risk of prostate problems, this
could suggest novel prevention and treatment strategies through
weight loss and lifestyle changes.33
3. Obesity and prostatitis
Prostatitis is a common but poorly deﬁned condition, without
clear diagnostic criteria and treatment approaches.34 Age, race, and
geographic region have been identiﬁed by several studies to be a
signiﬁcant risk factor for chronic prostatitis.35e37 Prostatitis is
found in approximately 10e14% of men of all ages and racial origin
and nearly 50% of men at some point in their life encounter this
condition.5,19,37e42
There is currently no evidence about the relationship between
obesity and prostatitis. Although it still remains unclear, there are
few studies reviewing this relationship between obesity and pros-
tatitis using the BMI parameter. Wallner et al12 showed that
increased BMI has a protective effect on prostatitis risk after
adjustment for age.12 The odds of having a history of prostatitiswere
decreased by approximately 68% in obese men (BMI> 30 kg/m2)
when compared with men with a BMI of 25 kg/m2. This result is
likely due to the inﬂuence of physical activity on this relationship.
This study revealed that the odds of developing prostatitis in men
whowere vigorously physicallyactivewere 67%. In the same study, a
larger percentage (57.8%) of the men characterized as obese were
found to engage in vigorous exercise compared with overweight
(4.8%) and normal weight men (22.4%). Unfortunately, this partic-
ular study did not state the type of exercise performed by their
participants. Studies regarding this subject are paramount in
determining the risk of prostatitis inpeoplewith obesity. Thusmany
studies relating obesity and prostatitis are still needed andmight be
enlightening.
4. Obesity and BPH
BPH is the most common nonmalignant medical condition of
the prostate occurring in middle aged and older men.43 BPH is ahistological diagnosis associated with unregulated proliferation of
connective tissue, smooth muscle, and glandular epithelium
within the prostatic transition zone. Cellular proliferation leads to
increased prostate volume and increased stromal smooth muscle
tone.44 According to a recent epidemiological study, BPH affects
70% of men aged 60e69 years old and 80% of those 70 years
old.42
Many studies have shown that obese men have a higher risk for
BPH, as shown in Table 1.19,33,45e49,51 Even though there are many
standards, according to patients' characteristics (e.g., race) in cat-
egorizing patients' BMI andWC to diagnose obesity, all studies have
resulted in the same conclusion that obesity, central or general, is a
risk factor for BPH and worsened urinary symptoms. Increased WC
was signiﬁcantly and positively associated with prostate volume,
serum prostate-speciﬁc antigen, and International Prostate Symp-
tom Score, and therefore worsened the patients lower urinary tract
symptoms.19
There are many hypotheses that have been suggested for the
effect of obesity on BPH. Central obesity exerts several systemic
effects. Obesity will increase intra-abdominal pressure, which in
turn increases bladder pressure and intravesical pressure, with
the potential to exacerbate and cause worsened BPH symp-
toms.52 Another mechanism is altered endocrine status.
Increased estrogen to androgen ratio due to the enzyme P450
aromatase expressed by fat tissue.53 Therefore, an adipose tissue
mass will increase the aromatase activity and the conversion of
the androgens to estrogens (testosterone to estradiol and an-
drostenedione to estrone). Increased fat mass and aromatase
activity reduces the testosterone concentrations and allows for
the preferential deposition of abdominal adipose tissue/VAT as
the positive caloric balance which results in a hypogonadal
obesity cycle. Continued production of estradiol caused by fat
mass accumulation may result in gonadotropin suppression, with
a further reduction in the testosterone levels and the develop-
ment of a progressive hypogonadal state thus favorable in the
development of BPH.54 Increased sympathetic nervous activity in
central obesity has been known to inﬂuence the development of
BPH and the severity of urinary obstructive symptoms.38,45
However, difﬁculties in measuring sympathetic nervous activity
and heterogeneity in characterizing obesity may cause lack of a
conclusive relationship between sympathetic nervous activity
and obesity.45
Another proposed hypothesis is the inﬂammation process and
oxidative stress.29,55e57 Central obesity promotes microvascular
disease and inﬂammation, which in turn contributes to ischemia,
oxidative stress, and an intraprostatic environment favorable to
BPH.52 Changes in regulation of programed cell death may lead to
hyperplastic and precancerous transformation.40 In patients with
central obesity, there is evidence of increased chronic inﬂamma-
tion cause by the secretion of inﬂammation cytokines by the
visceral fat.50,58 Inﬂammation is a very intricate phenomenon
involving humoral (cytokines) and cellular (leucocyte, monocyte,
and macrophages) elements.57 In normal mechanisms, there is a
balance between proinﬂammatory (growth factor release and
angiogenesis) and anti-inﬂammatory (decrease of those pro-
cesses) processes, leading to inﬂammation resolution.59 However,
in chronic inﬂammation, mainly consisting of chronically activated
T cells and mononuclear phagocytes, there is persistence of
proinﬂammatory factors causing disturbances in the inﬂammation
process. This will further promote the inﬂammation process by
releasing more progrowth cytokines as well as various other
growth factors.59 T cells inﬂuence matrix formation and potential
epithelial secretions. They then promote prostate stromal and
epithelial proliferation/hyperplasia by inducing ﬁbromuscular
Table 1
The Risk of Benign Prostate Hyperplasia Relating to Obesity in Various Studies Based on Obesity Status (Body Mass Index and Waist Circumference).
Study reference Population studied (n) Control (n) Findings
Lee et al19  WC  100 cm (119)
 WC 90e99 cm (137)
 WC < 90 cm (153) Higher WC related to worse BPH symptoms (OR¼ 1.68, P¼ 0.002)
Giovannucci et al45  WC  109 cm (258)  WC  89 cm (415) Abdominal obesity associated with BPH (OR¼ 2.38, 95% CI 1.42e3.99
Wang et al48  WC  90 cm (270)  WC< 90 cm (216) The only independent risk factor of BPH is abdominal overweight/
obesity (OR 2.112, 95% CI 1.284e3.47, P¼ 0.003)
Rohrmann et al51  WC > 102 cm (2,797)  WC < 94 cm
(not clearly mentioned)
Higher WC was more likely to have LUTS (OR¼ 1.48, 95% CI 0.87e2.54).
Parsons et al33  BPH (91)  Control (331) Odds ratio for BPH
 Overweight men (BMI, 25e29.9 kg/m2): 1.41 (95% CI, 0.84e2.37)
 Obese men (BMI, 30e34 kg/m2): 1.27 (95% CI, 0.68e2.39)
 Severely obese men (BMI> 35 kg/m2); 3.52 (95% CI, 1.45e8.56;
P< 0.01)
Xie et al49  BPH (317)  Control (332)  Overweight men increased risk of BPH (OR: 1.61, 95% CI 1.15e2.26)
 Obese men (OR 2.07, 95% CI 1.04e4.14)
 The OR increased 1.12-fold per increase in 1 unit of BMI (95% CI 1.06
e1.18)
Lee et al46  Obese (58)
 Overweight (38)
 Normal weight (50) Higher BMI ( 25 kg/m2) and central obesity were at signiﬁcantly
increased risk of BPH (OR¼ 4.88, P¼ 0.008)
Penson et al47  Severely obese (942)
 Obese (1,512)
 Overweight (2,691)
 Normal weight (2,046) Worsened BPH symptoms were signiﬁcantly associated with a BMI of
 35 kg/m2 (OR 1.38, 95% CI 1.17e1.63).
BMI, body mass index; BPH, benign prostate hyperplasia; CI, conﬁdence interval; LUTS, lower urinary tract symptoms; OR, odds ratio; WC, waist circumference.
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prostate enlargement corresponds to the extent and severity of the
inﬂammation.39
There are several inﬂammation processes associated with BPH
development in obese patients, such as toll-like receptor (TLR),
cyclooxygenase-2 (COX-2), and macrophage inhibitory cytokine-1
(MIC-1). TLR is a transmembrane receptor responsible for the
initiation of a range of host-defense mechanisms in response to
microbial products28 and can be found in prostate tissue and acts as
a proinﬂammatory cytokine. Poulain-Godefroy et al28 observed an
increased expression of TLRs in VAT of approximately 1.35 to 1.4
fold compared with SAT. This expression in fat cells induces cyto-
kine secretion, which triggers further inﬂammation.28
Chronic inﬂammation continuously produces COX-2, which
modulates the production of angiogenic factors to induce
angiogenesis, increases the carcinogenic potential of cells
through the oxidation of procarcinogens to carcinogens, increases
cell growth, and decreases apoptosis.40 Nitric oxide is one of the
free radicals associated with prostatic inﬂammation. It also en-
hances COX activity, which has been detected in all inﬂammatory
cells in the epithelium and interstitial spaces of human prostate
tissue.56 Di Silverio et al39 and Hamid et al40 showed that, in
human BPH tissue, COX-2 could produce a signiﬁcant increase in
prostate cell apoptotic inhibitory activity causing cell prolifera-
tion in the prostate. The relationship between COX-2 and central
obesity in humans is still debatable; however, a study by Ghoshal
et al27 have found that in mice, genetic deﬁciency of COX-2
resulted in a signiﬁcant reduction in total body weight and
percent body fat.
Induction of anti-inﬂammatory factors such as MIC-1 is an early
response due to inﬂammation in the prostate.60 MIC-1 was down
regulated in BPH tissues compared with normal prostate tissue.40
This may be caused by gland destruction by inﬂammatory in-
ﬁltrates, followed by replacement of the stromal component in
symptomatic BPH.41 However, Dostalova et al61 revealed that cen-
tral obesity is associated with signiﬁcantly higher serum MIC-1
levels, although the exact mechanism is still poorly understood. It
is possible that expression of circulating MICs might be in a
different concentration than prostatic MICs, especially in the tran-
sition zone (site of BPH).405. Obesity and PCa
PCa is the second most commonly diagnosed cancer and the
sixth most common cause of cancer-related mortality among men
worldwide.62 According to GLOBOCAN 2012,63 it was shown that
PCa is the third most common cancer in men (after lung and
colorectal cancer) and has around a 9.8% incidence and 8.9% mor-
tality amongst all cancers in Indonesia.
Studies have reported the association between obesity and
many cancers including PCa.64e67 A detailed explanation from
many studies is shown in Table 2.22,68e72 Throughout many studies
it is shown that obesity is a risk factor for the development of
prostate cancer (odds ratio 1.097e2.47) and even the progression
towards high grade disease (odds ratio 1.49e2.56).
There are several mechanisms most commonly proposed to
explain the association between obesity and PCa, which are the
insulin/insulin-like growth factor (IGF)-1 axis, altered sex hor-
mones (decreased serum testosterone and peripheral aromatiza-
tion of androgen), and adipokine signaling caused by
inﬂammation.62,64 Insulin alone does not induce somatic cell mu-
tations; however, it has anabolic, antiapoptotic, and, in supra-
physiological concentrations, mitotic effects. Activation of insulin
on the intracellular transduction pathway may affect the growth of
cancer cells, especially when high concentrations of insulin are
present, as occurs in obesity.64 Central obesity and hyper-
insulinemia are associated with increased circulating amounts of
bioactive IGF-1, a growth factor with a recognized pathogenic role
in many cancers, which in turn elevate circulating growth factors.
Gallagher and LeRoith73 conﬁrmed that growth hormone receptor
is upregulated by an increase of insulin concentration in portal
circulation thus increasing growth hormone receptor signaling and
hepatic IGF-1 synthesis, in hyperinsulinemia state, which induces
neovascularization and prevents apoptosis.64
The androgens testosterone and dihydrotestosterone have been
known to have an important role in the development of the pros-
tate gland, PCa progression, and involvement in earlier stages of
PCa development. Increased serum insulin levels inhibit hepatic sex
hormone-binding globulin (SHBG) synthesis. SHBG, a carrier pro-
tein that speciﬁcally binds circulating testosterone and dihy-
drotestosterone and reduces their availability to tissues, correlates
Table 2
The Risk of Prostate Cancer Relating to Obesity in Various Studies Based on Obesity Status (Body Mass Index and Waist Circumference).
Study reference Population studied (n) Control (n) Findings
De Nunzio et al22  PCa (246)  Control (422) Central adiposity was signiﬁcantly associated with PCa (OR 1.66, CI 95% 1.05e2.63,
P¼ 0.03) and high-grade disease (OR 2.56, CI 95% 1.38e4.76, P¼ 0.003)
Nemesure et al70  PCa (963)  Control (941) WC of  102 cm had an OR of 1.84 (95% CI 1.19e2.85) compared with those with WC of <
90 cm
Irani et al69  PCa (194)  Control (194) Obesity was signiﬁcantly associated with PCa (OR 2.47, 95% CI 1.41e4.34)
De Nunzio et al68  PCa (363)  Control (522) Obesity was signiﬁcantly associated with PCa (OR 1.097, 95% CI 1.029e1.171)
Rundle et al72  PCa (494)  Control (494) Obesity at the time of biopsy was associated with PCa incidence during follow-up (OR
1.57; 95% CI 1.07e2.30)
Park et al71  Obese (408)  Normal weight (805) Obesity was signiﬁcantly associated with a higher risk of detection on PCa in biopsy
patients (OR¼ 1.446, P¼ 0.024)
Obesity was signiﬁcantly associated with a higher rate of high-grade PCa detected from
the biopsy (OR¼ 1.498, P¼ 0.039)
BMI, body mass index; CI, conﬁdence interval; OR, odds ratio; PCa, prostate cancer; WC, waist circumference.
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bound/unavailable testosterone, also correlates inversely with BMI
and insulin. This relationship can be explained by long-loop feed-
back inhibition of pituitary luteinizing hormone secretion by
bioavailable (non-SHBG bound) testosterone, which leads to
reduced testicular androgen synthesis. In obese men, total testos-
terone, SHBG, luteinizing hormone pulse amplitude, diurnal lutei-
nizing hormone, and bioavailable testosterone are all reduced.74
Men with PCa who have low testosterone tend towards a more
aggressive phenotype. However, the low T environment in obese
menmay be one plausible link between obesity and aggressive PCa,
although the exact mechanisms remain unknown.62
Prabhat et al31 concluded that central obesity had a higher
correlation with hormonal and metabolic alterations compared
with BMI, which may contribute to various mechanisms, such as
chronic inﬂammation.31 Central adiposity, which was evaluated in
European patients at risk of PCa, is a state of chronic subclinicalFig. 1. Possible mechanisms for obesity-related prostate cancer progression. IGF-1, insulin
prostate cancer: a role for adipokines” by T. Mistry, J.E. Digby, K.M. Desai, H.S. Randeva, 2007
Urology. Adapted with permission.inﬂammation associated with adipokine signaling such as higher
levels of leptin, lower levels of adiponectin, which have, though
controversially, been associated with PCa.22 Leptin, the adipocyte-
derived hormone, is elevated in central obesity and exerts a pre-
dominantly protumor effect in human PCa cell lines, by promoting
angiogenesis and increased sympathetic nervous system activity.75
In contrast to leptin, adiponectin has largely antitumor effects by
inhibiting cancer cell growth, metastasis, inhibiting dehy-
drotestosterone, and it inhibits inﬂammation by inhibiting the ac-
tivity of mature phagocytic macrophages; however, serum levels of
adiponectin are reduced in central obesity.76 All of these mecha-
nisms result in increased proliferation, decreased apoptosis, and
transition from androgen dependence to androgen independence.
The mechanism of how obesity might affect PCa is shown in Fig. 1.
It is thought that androgens might promote the initiation and
progression of well-differentiated PCa, while protecting against
poorly differentiated cancers.74 However, an increased risk for-like growth factor-1, SHBG, sex hormone-binding globulin. Note. From “Obesity and
, European Urology, 52, p. 46e53. Copyright 2007, Elsevier B.V. European Association of
Parikesit et al / Obesity and prostate disease 5poorly differentiated PCa has been associated with hyper-
insulinemia and leptin.22,31,58,73,75,76 A recent study indicates that
obese people have low testosterone levels, raised insulin and leptin,
characteristics of adiposity, which increases the risk for poorly
differentiated, androgen dependent PCa.77
6. Conclusion
Central obesity is one of the modiﬁable risk factors in relation to
prostate diseases. Adipose tissue, favoring VAT, is an important risk
factor for the development of BPH and PCa. Manymechanisms have
been hypothesized to explain the correlation between obesity and
risk of BPH and PCa, such as increased estrogen-to-androgen ratio
and increased sympathetic nervous activity, promotion of inﬂam-
mation process, which in turn contributes to ischemia, oxidative
stress, and an intraprostatic environment favorable to BPH and PCa.
A greater understanding of the pathogenesis of prostate disease
and adiposity could allow the development of new therapeutic
markers, prognostic indicators, and drug targets. It may also pro-
vide scientiﬁc evidence to promote weight loss and other lifestyle
modiﬁcations as beneﬁcial adjuvant therapies for prostate diseases.
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